Department of Defense Prostate Cancer Research Programs FY11

 

The Fiscal Year 2011 (FY11) Defense Appropriations Act provides $ 80M to the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) to fund research that will eliminate death and suffering from prostate cancer.  This program is administered by the U.S. Army Medical Research and Materiel Command (USAMRMC) through the Office of the Congressionally Directed Medical Research Programs (CDMRP). 

 

A summary of PCRP funding opportunities is provided below.  Detailed descriptions of each of the funding opportunities, evaluation criteria, and submission requirements can be found in the FY11 PCRP Program Announcements.  Each Program Announcement is available electronically for downloading from the Grants.gov website (http://www.grants.gov), the CDMRP website (http://cdmrp.army.mil/) and the CDMRP eReceipt System (https://cdmrp.org).

 

Brief descriptions of each of these award mechanisms are available on the Congressionally Directed Medical Research Programs website at http://cdmrp.army.mil/funding/pcrp.shtml

 

 

Submission Deadlines:

 

Award Mechanisms with Emphasis on Innovation:

 

Idea Development Award

http://www07.grants.gov/search/search.do?&mode=VIEW&flag2006=false&oppId=89273

Pre-Application (Pre-proposal):  June 1, 2011

Application:  August 23, 2011

 

Synergistic Idea Development Award

http://www07.grants.gov/search/search.do?&mode=VIEW&flag2006=false&oppId=89274

Pre-Application (Pre-proposal):  June 1, 2011

Application:  August 23, 2011

 

 

Award Mechanisms with Emphasis on Impact:

 

Clinical Trial Award

 

 

Maximum funding $ 375K in direct costs *Preproposal is required; application submission is by invitation only *Supports rapid execution of clinical trials to test interventions with the potential to have a major impact on the treatment or management of prostate cancer *Studies in a broad range of areas may be submitted *Investigational New Drug or Investigational Device Exemption approvals, if applicable must be in place before submission of the application *Sufficient study material must be available for the study at the time the award is made *PI  must demonstrate availability and access to suitable human subject population that will support a meaningful outcome of the trial; population must be of sufficient size to clearly answer the objectives of the study *Clinical trials are expected to be initiated within 12 months of the award date.

Pre-application:  June 10, 2011

 

 

Application:  September 1, 2011

 

 

Impact Award

Maximum funding $ 750K in direct costs *Pre-propsoal is required; application submission is by invitation only *Supports high-impact studies towards reducing or eliminating the problem of overtreatment of primary prostate cancer *Multidisciplinary teams inclusive of clinical specialists are a key feature *Preliminary data to support feasibility are required.

 

 


Pre-Application:  June 10, 2011

 

Application:  September 1, 2011

 

 

Laboratory-Clinical Transition Award

Maximum funding $ 750K in direct costs *Preproposal is required; application submission is by invitation only *Supports product-driven preclinical studies of promising lead agents that have the potential to revolutionize prostate cancer clinical care *PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agent's mechanism of action *Preliminary data are required to demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans *Does not support target discovery, drug screening, device development, development of diagnostic biomarkers, studies of new combinations of conventional therapeutics in clinical testing or practice, or clinical trials *Supports research that ranges from preclinical study of the lead agent(s) through its cGMP production.

 

 


Pre-Application:  June 10, 2011

 

Application:  September 1, 2011

 


 

 

All applications must conform to the program announcements and application instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

A pre-application will be required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline.  Applications must be submitted through the federal government's single-entry portal, Grants.gov.  Requests for email notification of the program announcements release may be sent to help@cdmrp.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Points of Contact:

CDMRP Public Affairs

301-619-9783

CDMRP.PublicAffairs@amedd.army.mil